AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04569279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban (Rovaltro®) is a novel oral anticoagulant that acts selectively, reversibly, and potently on activated Factor X (Factor Xa) inhibiting a critical point on the coagulation cascade. Rivaroxaban has excellent bioavailability, rapid onset of peak anticoagulation effect, and predictable pharmacokinetic and pharmacodynamic properties making routine laboratory monitoring and dose adjustments almost unnecessary (11). Rivaroxaban is an extensively studied drug and has received approvals for anticoagulation in several preventive and therapeutic indications (11). Now medical literature has some solid evidence that Rivaroxaban is comparable with other anticoagulants in terms of efficacy. Several studies imply that Rivaroxaban may have a lower risk of major bleeding (11). Several reports and small case-series (12,13) suggest that rivaroxaban may be beneficial as Warfarin in the treatment of cerebral venous thrombosis (CVT) with less or no major complications.
Study NCT04569279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin (Orfarin®) is the most popular vitamin K antagonist and is considered the standard of care in many venous and arterial anticoagulation indications with extensive clinical experience regarding its use. This inexpensive and effective drug has a narrow therapeutic window that is affected by diet changing and many drug interactions, making frequent monitoring with prothrombin time (PT)/international normalized ratio (INR) highly important.(14)
Study NCT00916006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 Gel
Description: 0.015%, three day treatment
Study NCT00916006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle gel, three day treatment
Study NCT03008941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Capsules with fecal microbiota from healthy donors
Study NCT03008941 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT02189603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant (E. Coli) Hepatitis E Vaccine
Study NCT02763553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Feed
Description: A low-carbohydrate, high-fat feed designed to induce a ketotic state.
Study NCT02763553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Feed
Description: Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
Study NCT02871765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education related Warfarin
Description: Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
Study NCT04161222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Experimental group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
Study NCT04161222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Control group will perform a typical warm-up of competitive football
Study NCT02117115 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced computed tomography
Description: CT scan performed between Day +7 and Day +14.
Study NCT02117115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioversol
Description: To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
Study NCT01664234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laryngoscopy with oxygen
Description: Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
Study NCT01664234 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laryngoscopy without oxygen
Description: Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
Study NCT02189603 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant (E. Coli) Hepatitis E Vaccine
Study NCT03840070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenfill
Description: Maximum: 22ml
Study NCT06239662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Group
Description: The first part of each meeting, lasting 45 minutes, will be held only with children and young people, while parents will wait in the waiting room. At the end of the first part, for each meeting, the children will be asked to make a commitment relating to the topics covered, which will be verified in the following meeting. Once the part with the patients has concluded, they will be accompanied to an adjacent environment where a pediatrician volunteer will be waiting for them and will offer fun and socialization activities. In the meantime, the parents will be seated and will address, together with the team staff, the same issues discussed with their children, again for a duration of approximately 45 minutes. Parents will also be invited to make a commitment similar to that required of children.
Study NCT06239662 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The dietician will meet individually each child together with parents. Dietician will provide nutritional advices.
Study NCT01675830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat Retention Head Wrap
Description: Applied to infant's heads during the rewarming phase of CBP surgery
Study NCT00690469 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00690469 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02196012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Study NCT02196012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention control condition
Study NCT04410705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave theraphy for hamstring tendinopathy
Description: For hamstring tendinopathy; a total of 2000 impulses will be done. We will apply twice a week and 5 times in total.
Study NCT04410705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave theraphy for quadriceps tendinopathy
Description: Energy flux density will be 0.58mJ/mm2 (2 bar) with 2000 impulses. We will perform twice a week, 5 times in total.
Study NCT04410705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave theraphy for achilles tendinopathy
Description: Each session consisted of 2400 impulses will be administered with an energy flux density ranged from 0.17 to 0.25 mJ/mm2 (1.7-2.5 bar). We will perform once a week, 3 times in total.
Study NCT03677947 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and response prevention
Description: ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, participants will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention). Exercises will consist of both exposure in vivo (i.e. exposure in real life situations) and/or imaginal exposure according to recommendations.
Study NCT03677947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inference-based cognitive therapy
Description: The treatment primarily targets the dysfunctional reasoning that gives rise to obsessional doubts and overvalued ideas. IBCT does not include exposure in vivo, but instead, aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
Study NCT02069847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.~The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.~Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide.
Study NCT02386072 — intervention group
Intervention type: DRUG
Intervention: mirabegron
Description: oral
Study NCT00899535 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Study NCT00899535 — intervention group
Intervention type: GENETIC
Intervention: RNA analysis
Study NCT00899535 — intervention group
Intervention type: GENETIC
Intervention: microarray analysis
Study NCT00899535 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Study NCT00899535 — intervention group
Intervention type: GENETIC
Intervention: polymorphism analysis
Study NCT04631133 — intervention group
Intervention type: DEVICE
Intervention: Lumbar Implant for Stiffness Augmentation (LISA)
Description: The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).
Study NCT01573819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK356278
Description: Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
Study NCT01573819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
Study NCT02634281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Study NCT01773772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls \< 42kg and 50 mg given to those or = to 42 kg.
Study NCT01773772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
Study NCT01715714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin Recapture Therapy
Description: Given 12h and 2h before CABG
Study NCT01715714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given 12h and 2h before CABG.
Study NCT02793466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab; MEDI4736
Description: IV Infusion every 2 weeks for a maximum of 26
Study NCT00590798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Patient will walk within 30 minutes of vascular closure system procedure
Study NCT02484287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Integra External Drainage Catheter.
Description: Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
Study NCT02484287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Ventriclear EVD Antibiotic Catheter
Description: Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
Study NCT02484287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Codman Bactiseal EVD Catheter Set
Description: Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
Study NCT02386072 — intervention group
Intervention type: DRUG
Intervention: antimuscarinic medication
Description: oral
Study NCT05360225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: therascreen® KRAS RGQ PCR Kit
Description: The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.
Study NCT02232932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAPECITABINE-Radiotherapy -Liver Transplantation
Description: CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
Study NCT02232932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RESECTION
Description: Intent-to-treat R0 liver resection
Study NCT02979717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein, high fiber dietary supplement
Study NCT02979717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low protein, low fiber comparator
Study NCT01234207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard, non-free-form, non-customized PAL spectacles
Description: Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
Study NCT01234207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Individually customized free-form surfaced PAL spectacles
Description: Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
Study NCT00787605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
Study NCT00787605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
Study NCT00787605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
Study NCT04685343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing
Description: Quantitative sensory testing (QST) consisting of 4 pain induction and sensory sensitivity tasks (i.e., pressure applied to the thumbnail, arms, shoulders, and lower abdomen, a cold water task, and one video-watching task).
Study NCT04685343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional magnetic resonance imaging (fMRI) session consisting of structural and functional brain scans.
Study NCT03168438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letetresgene autoleucel
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion
Study NCT03168438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letetresgene autoleucel with pembrolizumab
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks
Study NCT03168438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
Study NCT03168438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
Study NCT03168438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is available as an IV infusion
Study NCT02049320 — intervention group
Intervention type: DRUG
Intervention: Remifentanil
Study NCT04536025 — intervention group
Intervention type: OTHER
Intervention: Qualitative focus group interviews
Description: Prosthetists and/or expert working group members will participate in qualitative focus group interviews up to 120 minutes in length.
Study NCT04536025 — intervention group
Intervention type: OTHER
Intervention: Qualitative semi-structured interviews
Description: People with lower limb amputation and/or expert working group members will participate in qualitative individual, semi-structured interviews approximately 60 minutes in length.
Study NCT01598168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
Study NCT00366834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenous
Study NCT00366834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone intravenous
Study NCT02572193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: To determine the feasibility of same-day discharge following a POEM procedure
Study NCT02271373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: increasing time spent outdoors
Description: The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
Study NCT03235843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AAIR pacing
Description: Rate adaptive pacing using a MV sensor.
Study NCT03235843 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DDI-pacing
Description: Rate adaptive pacing OFF
Study NCT00366834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron oral tablets
Study NCT02325661 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cognitive interviewing
Description: For the individual cognitive interviews we are using the two techniques to think aloud and the verbal probing. To think aloud means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the verbal probing technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation.
Study NCT03191240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressins
Description: Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation
Study NCT03191240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study NCT00208299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: 0.4 mg, bolus intravenous injection
Study NCT00208299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: 0.14 mg/kg/min for 6 minutes, intravenous infusion
Study NCT00410202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets, Oral, 1mg, once daily, 100 weeks
Study NCT00410202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tablets, Oral, 300 mg, once daily
Study NCT00410202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Tablets, Oral, 10mg, once daily, 100 weeks